Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afamelanotide Implants in Erythropoietic Protoporphyria (CUV017)
NCT04053270Phase 3Completed
- Sponsor
- Clinuvel Pharmaceuticals
- Start
- May 2007
- Primary completion
- Dec 2009
- Modality
- Peptides, Small Molecules
01
Overview
A Phase 3 trial of Afamelanotide in erythropoietic protoporphyria (EPP), sponsored by Clinuvel Pharmaceuticals. Started May 2007; status: completed.
02
Drugs
Afamelanotide
03
Conditions
erythropoietic protoporphyria (EPP)
Beyond the preview
Go deeper on NCT04053270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04053270.